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The nucleotide sequence of the env gp85-coding domain from two avian sarcoma and leukosis retrovirus
isolates was determined to identify host range and antigenic determinants. The predicted amino acid sequence
of gp85 from a subgroup D virus isolate of the Schmidt-Ruppin strain of Rous sarcoma virus was compared
with the previously reported sequences of subgroup A, B, C, and E avian sarcoma and leukosis retroviruses.
Subgroup D viruses are closely related to the subgroup B viruses but have an extended host range that includes
the ability to penetrate certain mammalian cells. There are 27 amino acid differences shared between the
subgroup D sequence and three subgroup B sequences. At 16 of these sites, the subgroup D sequence is identical
to the sequence of one or more of the other subgroup viruses (A, C, and E). The remaining 11 sites are specific
to subgroup D and show some clustering in the two large variable regions that are thought to be major
determinants of host range. Biological analysis of recombinant viruses containing a dominant selectable marker
confirmed the role of the gp85-coding domain in determining the host range of the subgroup D virus in the
infection of mammalian cells. We also compared the sequence of the gp85-coding domain from two subgroup
A viruses, Rous-associated virus type 1 and a subgroup A virus of the Schmidt-Ruppin strain of Rous sarcoma
virus. The comparison revealed 24 nonconservative amino acid changes, of which 6 result in changes in
potential glycosylation sites. The positions of 10 amino acid differences are coincident with the positions of 10
differences found between two subgroup B virus env gene sequences. These 10 sites identify seven domains in
the sequence which may constitute determinants of type-specific antigenicity. Using a molecular recombinant,
we demonstrated that type-specific neutralization of two subgroup A viruses was associated with the
gp85-coding domain of the virus.
The envelope glycoproteins on the surface of a retrovirus
particle specify the major determinants of host cell recogni-
tion and penetration (59). The env gene of avian retroviruses
encodes two proteins, gp85 and gp37, which are synthesized
as a single precursor polypeptide, processed, and trans-
ported to the cell membrane, where they remain linked by
disulfide bonds (9, 21, 27, 29, 35, 36, 39).
Individual isolates of the avian sarcoma and leukosis virus
(ASLV) group interact with different host cell components,
presumably specific host cell receptors, at an early stage in
infection. The presence of polymorphism in these determi-
nants within the host population gives rise to a host range
phenomenon in which different virus isolates display a
characteristic pattern of infectivity for cells derived from
inbred lines of chickens (57). This pattern of host range is
one criterion used to divide the various virus isolates into
subgroups. The viral determinants that give rise to the
subgroup phenotype lie within the env gene (11, 31, 58).
Comparison of the nucleotide sequence of the gp85-coding
domain from viruses of different subgroups has revealed
specific regions of sequence variability (8, 17, 45). Recently,
analysis of molecular recombinants has shown that the major
determinants of host range lie within the gp85-coding domain
(8, 16, 17).
Three dominant autosomal loci, TV-A, TV-B, and TV-C,
have been identified in chickens as the determinants of host
susceptibility to subgroup A, B, and C viruses, respectively
(13-15, 41). Chicken cells resistant to subgroup B ASLV are
equally resistant to subgroup E viruses and partially resis-
tant to subgroup D viruses (57). In addition, subgroup B
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viruses interfere to various degrees with infection by sub-
group D and E viruses (2, 19, 26). These observations
suggest that subgroup B, D, and E viruses use the same
receptor or related receptors when infecting chicken cells.
Subgroup D viruses are phenotypically distinct from sub-
group B viruses in two ways. (i) Most inbred chicken lines
show some level of susceptibility to subgroup D viruses even
though certain lines are highly resistant to subgroup B
viruses (19). (ii) Subgroup D viruses are able to penetrate a
variety of mammalian cells (6, 19). One manifestation of this
mammal tropism is the ability of subgroup D strains of Rous
sarcoma virus (RSV) to produce tumors when injected into
certain mammals (19, 52).
Another criterion used to define the subgroup phenotype
is antigenicity. Immune chicken sera show specificity in
reacting with viruses from the same subgroup (30). Fre-
quently, these sera show even greater specificity in that they
also recognize type-specific antigens present on the particu-
lar virus isolate used for immunization (30). Thus, antigenic
variation is observed at two levels: between viruses that use
different host cell receptors (subgroup specific) and within a
group of viruses that use the same receptor (type specific).
In this report, we extend our molecular analysis of the
ASLV env gene product, gp85, to include a subgroup D virus
isolate. We compare the predicted amino acid sequence of
Schmidt-Ruppin strain subgroup D (SR-D) RSV with the
reported sequences of other subgroup viruses to identify
determinants of mammal tropism for the subgroup D virus.
We also present the sequence of the gp85-coding domain of
the subgroup A virus Rous-associated virus type 1 (RAV-1)
and discuss the role of sequence differences in the antigenic
variability frequently seen in subgroup A and B viruses.
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Finally, we used recombinant viruses to investigate the role
of the gp85-coding domain in defining host cell penetration
by subgroup D and A viruses in a variety of avian and
mammalian cell lines and in defining the site of action of
subgroup- and type-specific neutralizing antibodies.
MATERIALS AND METHODS
Cells, viruses, and antisera. Fertile chicken eggs were
obtained from the Regional Poultry Research Laboratory,
East Lansing, Mich. Chicken embryo fibroblasts (CEF),
prepared from 11-day-old embryos, and QT6 cells were
maintained as described previously (8). Most mammalian
cell lines were maintained in Dulbecco minimum essential
medium supplemented with 10% fetal bovine serum. P19
cells were grown in Dulbecco minimum essential medium
supplemented with 7.5% calf serum and 2.5% fetal bovine
serum, and D98/HR1 cells were grown in RPMI medium
containing 10% fetal bovine serum.
Viral genomes were obtained as molecular clones. pSRD-
11, an infectious clone of SR-D RSV, was obtained from D.
Shalloway (47). Plasmid p779NC327AC28F, which contains
a complete copy of the SR-A RSV genome with a unique
ClaI site in place of the v-src insert, was obtained from S.
Hughes (28). pRAV1OR, an infectious clone of the RAV-1
genome, was obtained from L. Sealy (46). Polyclonal
chicken antisera against RAV-1 and a nontransforming de-
rivative of SR-A RSV were a gift from R. Shuman. The
antisera were raised in Spafas gs- chf C/O chickens.
Plasmids and bacteria. The molecular recombinant of
subgroup A and D viruses was constructed by a strategy
similar to that described previously (8). Plasmid pAV-V1,
which contains an intact copy of the SR-A RSV genome, was
cleaved with restriction enzymes KpnI and SalI to excise a
1. 1-kilobase (kb) fragment that spans most of the gp85-
coding region. This fragment was replaced with an equiva-
lent fragment from the pSRD-11 clone.
The construction of pANV-A will be described elsewhere
(J. C. Olsen, W. P. Osheroff, and R. Swanstrom, manuscript
in preparation). This plasmid contains the neomycin resis-
tance gene (neor) from pSV2neo (49) cloned into the ClaI site
of p779NC327AC28F. The resulting plasmid contains the
replicative genes of SR-A RSV, with the v-src gene replaced
by the neor gene. pANV-D and pANV-Al were constructed
from pANV-A by removing the KpnI-to-SalI restriction
fragment and replacing it with the equivalent fragment from
pSRD-11 and pRAVIOR, respectively. A similar strategy
was used to construct a neor plasmid containing a subgroup
E recombinant virus genome, pANV-E (8). All plasmids
were propagated in either the HB101 or DH-1 strain of
Escherichia coli.
DNA transfection and host range analysis. Each bacterial
plasmid containing an intact viral genome was transfected
into C/O chicken cells by the polybrene-dimethyl sulfoxide
protocol of Kawai and Nishizawa (33) to generate virus. The
presence of virus in the medium was detected by measuring
virus-associated reverse transcriptase activity (8, 54). Host
range was tested by two assays. (i) Virus growth in different
avian cells was monitored by the appearance of virus-
associated reverse transcriptase in the culture medium. (ii)
Cells were first plated at a density of 5 x 105 cells per 60-mm
(diameter) plate. On the next day, the cells were pretreated
with polybrene (55) at 20 jig of polybrene per ml in serum-
free medium and then infected for 2 h with virus containing
the neor gene. At 24 h later, the cells were placed in medium
containing Geneticin G418 (GIBCO Laboratories, Grand
Island, N.Y.). The concentration of G418 was chosen such
that sensitive cells were dead 7 to 10 days after selection was
applied. Mock-infected cells were maintained in parallel.
The number of G418-resistant colonies was scored 14 days
after infection.
Virus neutralization. QT6 cells were plated at a density of
2 x 105 to 5 x 105 cells per 60-mm plate. On the following
day, dilutions of chicken antiserum were first incubated with
virus for 30 to 40 min at 37°C in 1 ml of medium, followed by
2 h of incubation with the QT6 cells. For avian neo virus
subgroup E (ANV-E) infections, QT6 cells were preincu-
bated for 1 h with 10 ,ug of polybrene per ml. The cells were
subjected to selection with 140 pLg of G418 after infection,
and G418-resistant colonies were scored approximately 2
weeks later.
Immunofluorescence. CEF C/O cells were infected with
virus stocks of ANV-A, ANV-A1, and ANV-E. Virus pro-
duction was monitored by analyzing reverse transcriptase
activity in the medium of infected cells. Infected cells were
grown on glass cover slips, washed with phosphate-buffered
saline, and exposed to a 1:10 dilution of chicken antiserum
for 30 min to 1 h in serum-free medium. After incubation
with antibody, the cells were washed and fixed with 3.7%
formaldehyde for 15 min. The cells were then exposed to the
second antibody, a 1:20 dilution of fluorescein-conjugated
rabbit anti-chicken immunoglobulin G (IgG; Cooper Bio-
medical, Inc., West Chester, Pa.) for 30 min to 1 h. Cover
slips were mounted and viewed with a Leitz fluorescence
microscope.
DNA sequence analysis. The nucleotide sequence of both
SR-D RSV and RAV-1 was obtained by a combination of the
chemical cleavage method (37) and the dideoxy chain termi-
nation method (1, 44, 61). The complete sequence was
determined on both strands of DNA. Sequence analysis was
performed with programs obtained through Bionet IntelliGe-
netics, Palo Alto, Calif. Conservative amino acid changes
are defined as changes involving amino acids with similar
side chains. The six other sequences that were used in
various comparisons have been described previously as
indicated: SR-A RSV and RAV-2 (8); RAV-0 (8, 17); Prague
strain subgroup B (Pr-B) RSV (17); myeloblastosis-associ-
ated virus subgroup B (MAV-B) (32); and Pr-C RSV (45).
For simplicity, we have adopted the nomenclature of Dorner
and Coffin (16) for naming variable regions identified by
comparing sequences from different subgroup env genes.
RESULTS
Nucleotide sequence of the gp85-coding domain from SR-D
RSV and RAV-1. In Fig. 1, the nucleotide sequences of a
portion of the env gene of two ASLV isolates, RAV-1
(subgroup A) and SR-D RSV (subgroup D), are compared
with the sequences of subgroup B (RAV-2; 8), subgroup C
(Pr-C RSV; 45), and subgroup E (RAV-0; 8, 17) isolates. In
each case, the sequence begins at or adjacent to a conserved
KpnI site. Analysis of these sequence comparisons con-
firmed previous reports that sequence variability is clustered
within four domains (vrl, hrl, hr2, and vr3), with a fifth
domain (vr2) showing divergence in the subgroup B se-
quence only (16). Comparisons of examples of the most
divergent sequences (subgroups A, C, and D) indicated that
there is approximately 60% nucleotide sequence identity
within the variable domains and 90% identity within the
flanking conserved domains.
Analysis of the predicted amino acid sequence of the gp85-
coding domain from SR-D RSV. The predicted amino acid
J. VIROL.
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FIG. 1. Nucleotide sequence comparison of five avian sarcoma and leukosis viruses: RAV-1, subgroup A; RAV-2, subgroup B (8); Pr-C
RSV, subgroup C (45); SR-D RSV, subgroup D; and RAV-0, subgroup E (8, 17). The entire sequence of RAV-1 is given, along with nucleotide
differences of the other virus isolates. The sequence comparison begins at the unique KpnI site corresponding to position 4995 of Pr-C RSV
(45). Also shown are the beginning of the env gene and the first base encoding the mature gp85 protein (29). The Kpnl and Sall restriction
sites used to construct recombinant viruses (see the text) are underlined. The variable domains (vrl, vr2, hrl, hr2, vr3) have been described
previously (8, 16, 17). Symbols: -, sequence identity with RAV-1; *, gap introduced during sequence alignment; . ., sequence not completed
to the KpnI site.
sequence of the mature gp85-coding domain from SR-D RSV
is shown in Fig. 2 in comparison with that of two subgroup
B isolates (8, 32). Examination of positions of identity and
conservative amino acid changes showed extensive (92%)
homology over the entire length of the sequence. There are
15 positions at which B and D subgroup sequences are
identical yet different from subgroup A, C, and E sequences



























































78 BOVA ET AL.





SR-D F R G Y V S D T N C T T V G T H R L V S S *G I P G G P D N S T T L T Y R K V S C L L L K L N V S M
RAV-2 * L E P R* E Q L
MAV-B D L R* L
vr2 hrI
O a 0 00 O O' 0 0 149
SR-D W D E P P E L Q L L G S Q S L P N I A N I T Q I P G V A G G C I G F T P Y G S P A G V Y G W G R E E
RAV-2 L S T R S D D R




0 e000 00 199
V T H I L L T N P P D N P F F N R A S N S T E P F T V V T A D R H N L FK G S E Y C G A Y G Y R F W
D G N D K S K
D L G N D K S K
hr2
000000 00 00O249
SR-D E H Y N C S Q I R * N Y S I C E D V W G P G P E S W C A R T G G T W V N K S K E I N E T E P I S F
RAV-2 M Q W Q R P N T S Q F A F
MAV-B M S Q W Q R T S I Q A F
vr 3
I 0 A 299
SR-D T V N C T G S N L G N V S G C C G E A I T I L P L G A W V D S T Q G S F T K P K A L P P G I F L I C
RAV-2 P P E A





G D R A W Q G I P S R P V G G P C Y L G K L T M L A P N H T N I L K I L A N S S R T G I R R K R
I D Q
(0) D. B; B,D ,A,C,,orE (0) D. B;D A,C,orE (A)D'B;B ,AC, or E (0) D = B; B,D. A,C, or E
FIG. 2. Comparison of gp85-coding domains of subgroup D and B viruses. The entire predicted amino acid sequence is shown for the
subgroup D virus, while only differences from the subgroup D sequence are shown for the subgroup B sequences. The RAV-2 and MAV-B
sequences have been described previously (8, 32). The asterisk denotes a gap inserted during sequence alignment. The variable regions
identified by comparison of subgroup A, B, C, and E virus env' genes (vrl, vr2, vr3, hrl, and hr2; 8, 16, 17) are shown above the sequence.
The symbols above the sequence represent results of sequence comparisons between SR-D RSV (Fig. 1), RAV-2 (8), MAV-B (32), Pr-B RSV
(17), SR-A RSV (8), RAV-1 (Fig. 1), Pr-C RSV (45), and RAV-O (8, 17). The symbols correspond to the sequence relationships shown at the
bottom of the figure. There are five positions of difference between the subgroup D sequence and the two subgroup B sequences not noted
with a symbol. The serine at position 71 is also found in the Pr-B RSV sequence, indicating that this site is neither D specific nor B specific.
The threonine at position 171 represents a conservative amino acid change from the subgroup B sequence. There are three other sites not
included (E172, A227, and A267), since at these sites both the subgroup D and B sequences resemble the sequences of other subgroup viruses.
five variable domains, including the two large variable
domains (hrl and hr2). Since subgroup B and D viruses
probably use the same receptor on chicken cells, these B-
and D-specific positions may define some of the amino acids
that interact with the chicken cell receptor.
Of the 27 nonconservative amino acid differences between
the subgroup D and B viruses, 13 are unique to the subgroup
B sequence, with the amino acids at those positions in the D
sequence identical to those in the subgroup A, C, or E
sequence (Fig. 2, open circles). Twelve of the sites are
within the variable regions. There are 11 amino acid posi-
tions unique to the subgroup D isolate (Fig. 2, closed circles
and triangles). At six of these positions (Fig. 2, triangles) the
subgroup B sequence is similar to one of the other subgroup
sequences. In the remaining five positions (Fig. 2, closed
circles), the subgroup B and D sequences differ not only
from each other but also from the A, C, and E subgroup
sequences (B and D unique). These positions are clustered
into two small regions, one in each of the two large variable
regions (hrl and hr2).
Host range analysis of molecular recombinants between
subgroup A and D viruses. The host range determinants of
subgroup A, B, and E viruses lie within the 1.1-kb KpnI-to-
SalI restriction enzyme fragment (Fig. 1) that spans most of
the gp85-coding domain (8, 16). To extend these studies, we
made a molecular recombinant between the SR-A and SR-D
RSV genomes. The 1.1-kb KpnI-to-SalI restriction fragment
that includes all of the variable regions was removed from
SR-A RSV and replaced with the equivalent fragment from
the subgroup D genome (Fig. 1). Virus was generated from
the cloned genome after transfection of the cloned DNA
onto susceptible cells. The parental and recombinant viruses
were then tested for the ability to grow on different avian cell
lines as measured by the appearance of reverse transcriptase
activity in the medium of infected cells. The parental SR-A
RSV and the subgroup D recombinant grew well on C/O
CEF cells, which should be susceptible to all subgroup
viruses. Both viruses grew on C/E cells, and neither virus
grew on C/ABE cells. Only the SR-A RSV parent grew in the
continuous quail cell line QT6, consistent with previous
work which showed that QT6 cells are resistant to subgroup
B and D viruses (40). We concluded that the recombinant
with the subgroup D sequence cannot use either the sub-
group A or the subgroup C receptor. These results indicate
that for the subgroup D virus, as with subgroup A, B, and E
viruses, the region of the genome encoding the major deter-
minants of subgroup specificity can be localized to within the
1.1-kb KpnI-to-SalI restriction enzyme fragment.
To assess the infectivity of subgroup D viruses in mam-
malian cells, we constructed a virus that carries a dominant
selectable marker, the neor gene (49). Eucaryotic cells are
sensitive to the drug G418. Introduction of neor into these
cells confers resistance to G418 (12, 49). We used neor as a
marker to analyze the ability of a virus containing this gene
to enter a cell and express the gene product. Plasmid
pANV-A contains the replicative genes of SR-A RSV. In this
J. VIROL.
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construction, the v-src gene of RSV has been replaced with
neor under control of the simian virus 40 promoter, and the
pBR322 origin of replication (Olsen et al., in preparation).
pANV-D was derived from pANV-A by replacement of the
1.1-kb KpnI-to-SalI restriction fragment with the equivalent
fragment from SR-D RSV. Transfection of the plasmids into
susceptible chicken cells yielded infectious virus (ANV-A
and ANV-D). These virus stocks were then used to infect
various QT6 cells and various continuous mammalian cell
lines.
Table 1 shows a summary of the number of colonies of
G418-resistant cells obtained after exposure of the cells to
virus-containing medium. No G418-resistant colonies were
obtained in mock-infected cultures. As expected, the sub-
group A virus readily infected the quail cell line QT6, while
the subgroup D recombinant virus did not infect these cells.
The opposite result was obtained with the NIH 3T3-derived
clonal cell line 45b, which was readily infected by the
subgroup D virus but not by the subgroup A virus. Several
mouse cell lines, representing a variety of different tissue
types, were analyzed. The level of infectivity of the recom-
binant subgroup D virus (as measured by the number of
G418-resistant colonies per milliliter of virus-containing me-
dium) varied greatly, depending on the different cell types,
while the subgroup A virus was negative for infection. The
primate cell line COS7, which expresses the simian virus 40
T antigen (24), was also readily infected by the recombinant
subgroup D virus. Three human cell lines also showed some
level of infection by ANV-D. The mammal-tropic determi-
nants of subgroup D virus must, therefore, be largely en-
coded within the 1.1-kb fragment used to construct the
recombinant subgroup D virus. Surprisingly, one of the
human cell lines was also infected at a low level with the
subgroup A virus. Thus, susceptibility to infection by these
recombinant viruses varied greatly among different mamma-
lian cell lines, and infectivity with a subgroup A virus could
be detected, albeit at a low level, in one of the lines.
Type-specific antigenicity of two subgroup A viruses.
RAV-1 and SR-A RSV are two subgroup A virus isolates
that have been shown to produce type-specific neutralizing
antibodies in chickens (30). We confirmed this observation
by using virus generated from cloned DNA. ANV-A, the
virus produced upon transfection of pANV-A into suscepti-
ble cells, contains the replicative genes, including the env
gene, of SR-A RSV. We constructed a RAV-1 recombinant
virus, ANV-Al, that contains the KpnI-to-SaIl fragment of
RAV-1 in an otherwise ANV-A genetic background. Table 2
provides a summary of neutralization experiments with eight
different chicken antisera raised against either avian leukosis
virus subgroup A (ALV-A; identical to ANV-A but lacking
the neor gene) or RAV-1. Each of the four antisera raised
against ALV-A (a-ALVA-1 through -4) effectively neutral-
ized ANV-A at a dilution of 10 - 3.. Two anti-ALV-A antisera,
cx-ALVA-3 and -4, neutralized the RAV-1 recombinant
ANV-Al, but only at the highest concentration tested in
serum. The antisera raised against RAV-1 (at-RAVI-1
through -4) effectively neutralized the RAV-1 recombinant
ANV-Al at a dilution of 10-2 or 10-3. Two of the four
anti-RAV-1 antisera, a-RAV1-2 and -4, neutralized ANV-A
at a serum dilution of 10-1. None of the antisera neutralized
the subgroup E recombinant virus ANV-E. From these
results, we conclude that some, if not all, of the determinants
that give rise to type-specific and subgroup-specific neutral-
izing antibody response in chickens reside within the se-
quences defined by the KpnI-to-SalI restriction fragment
that encodes most of the gp85 env gene product.
We also investigated cell surface immunofluorescent stain-
ing of C/O CEF cells infected with ANV-A, ANV-A1, and
ANV-E. Table 2 summarizes the results for each of the
chicken antisera. For the anti-ALV-A antisera, good surface
fluorescent staining (i.e., good overall staining of cells, with
some brightly staining patches) was observed in cells in-
fected with ANV-A. Two of the anti-ALV-A antisera gave
good immunofluorescence for ANV-Al-infected cells, while
none of the anti-ALV-A antisera stained ANV-E-infected
cells. For the anti-RAV-1 antisera, good surface staining was
found only for cells infected with ANV-Al recombinant
virus. Three of the anti-RAV-1 antisera stained ANV-A-
infected cells weakly (poor overall staining; few patches of
bright staining). ANV-E-infected cells did not show signifi-
cant cell surface staining. Therefore, six of the eight antisera
primarily stained cells infected with the homologous virus
(i.e., ot-ALVA and ANV-A; a-RAV1 and ANV-Al).
Comparison of the gp85-coding domain of RAV-1 and SR-A
RSV. The predicted amino acid sequence of gp85 from
RAV-1 was compared with the sequence of another sub-
group A virus, SR-A RSV (Fig. 3). Of the 24 nonconserva-
tive amino acid differences between RAV-1 and SR-A RSV,
6 result in changes in potential glycosylation sites. There are
14 potential N-linked glycosylation sites that are highly
conserved between subgroup B, C, D, and E viruses. Three
of these sites are missing from the RAV-1 sequence, and a
different three are missing from the SR-A RSV sequence.
Among subgroup B, C, D, and E viruses, all 14 potential
TABLE 1. Host range of recombinant viruses
Titef' of: Amt (pLg/ml) of
Cell line Origin (tissue source) G418 used for Reference
ANV-D ANV-A selection
QT6 Quail (fibrosarcoma) 0 3.1 x 103 250 40
NIH 3T3 45b Mouse (fibroblast) 2.2 x 102 0 200 53
P19 Mouse (teratocarcinoma) 10 NTb 100 20
F9 Mouse (teratocarcinoma) 0 0 200 4
G2620 Mouse (glioma) 0 0 600 62
L-cell TK- Mouse (connective tissue) 0 0 400 34
Neuro-2a Mouse (neuroblastoma) 82 0 150 Klebe and Ruddlec
COS7 Monkey (kidney) 2.1 x 103 0 350 24
D98/HR-1 Human (epithelial cell-B-lymphocyte fusion) 14 5 300 23
A549 Human (lung carcinoma) 9 0 400 22
U-251 MG Human (glioma) 1.0 x 102 NT 350 5
a Virus titer, Number of G418-resistant colonies per milliliter of virus-containing medium.
b NT, Not tested.
c R. J. Klebe and F. H. Ruddle, J. Cell. Biol. 43:69, 1969.
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TABLE 2. Virus neutralization and cell surface immunofluorescent staining
ANV-A ANV-Al ANV-E
Serum
Neutralization' Fluorescenceb Neutralization Fluorescence Neutralization Fluorescence
o-ALVA-1 3 + +
oa-ALVA-2 3 + +
ot-ALVA-3 3 + + 1 ++ - -
a-ALVA-4 3 + + 1 + + - -
a-RAV1-1 - + 2 + + - -
a-RAV1-2 1 + 3 + + - -
cx-RAV1-3 - 2 + + - -
a-RAV1-4 1 + 2 + + - -
a Negative logarithm of the greatest antiserum dilution that resulted in more than a 70% reduction of virus titer as measured by the number of G418-resistant.
colonies of QT6 cells. Each antiserum was tested in duplicate or triplicate for both ANV-A and ANV-Al virus stocks. ANV-E was tested with antiserum dilutions
of 10-2 and 10-'. The symbol - indicates that virus neutralization was not found at the lowest antiserum dilution tested (10-').
b Immunofluorescent cell surface staining of C/O CEF infected with ANV-A, ANV-Al, and ANV-E. Intensity of staining was judged as follows: + +, easily
detected; +, weak; -, background levels. Primary antibody was used at a 1:10 dilution, and fluorescein-conjugated second antibody was used at a 1:20 dilution.
glycosylation sites are completely conserved, with the ex- tween these two different subgroup A viruses than between
ception of the loss of 1 site in the subgroup D sequence and either different subgroup B viruses or viruses from different
of 1 site in the MAV-B sequence. The only other change in subgroups.
glycosylation is the addition of one site in hr2 in the The remaining 18 nonconservative amino changes be-
subgroup B and D sequences. Overall, there appears to be tween RAV-1 and SR-A RSV are scattered over the gp85
far greater potential for heterogeneity in glycosylation be- sequence. By comparison, there are 16 nonconservative
so
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SR-A HK T E M
RAV-2 V T H I L L T DPG N N P F F D K A S N S s K P F T V V T A D R H N L F M G S E Y C G A Y G Y R F W
MAV-B
_hr2 241
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vr3 > ' 290
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340
RAV-1 I C G D R A W Q G I P S R P V G G P C Y L G K L T M L A P N H T D I L K I L A N S S Q T G I R R K R
SR-A K V V R
RAV-2 I C G D R A W Q G I P SR P I G G P C Y L G K L T M L A P N H T D I L K I L A N S S Q T G I R R K R
MAV-B
FIG. 3. Comparison of the predicted gp85 sequences from viruses within the same subgroup. The predicted amino acid sequence of the
gp85-coding domain ofRAV-1 is shown, along with only the differences in the SR-A RSV sequence (8) as compared with the RAV-1 sequence;
both are subgroup A viruses. Also shown is the predicted amino acid sequence of RAV-2 (8), as well as the differences in the MAV-B
sequence (32) as compared with that of RAV-2; both are subgroup B viruses. Fifteen asparagine-linked potential glycosylation sites are
underlined in the RAV-2 sequence. The differences in potential glycosylation sites are as follows: RAV-1, loss of potential glycosylation at
sites 1, 2, and 12; SR-A, loss of potential glycosylation at sites 6, 7, and 14; MAV-B, loss of a potential glycosylation site at 2. Potential
glycosylation site 9 is specific to subgroup B and D viruses. The boxed regions (Ti through T7) indicate nonconservative amino acid sequence
changes between viruses belonging to one subgroup (RAV-1 and SR-A RSV) that cluster at equivalent or nearly equivalent positions of
nonconservative amino acid changes between viruses belonging to a second subgroup (RAV-2 and MAV-B). The variable domains described
in Fig. 1 are also shown. The MAV-B sequence ends, denoted by . . ., at the equivalent amino acid at position 301 of RAV-1. The amino acid
sequence numibering follows only the RAV-1 (and SR-A) sequence.
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amino acid differences found between RAV-2 and MAV-B,
two subgroup B viruses (Fig. 3). This comparison includes
only the first 300 amino acids of the MAV-B gp85-coding
domain (32). There appears to be some clustering of sites of
nonconservative amino acid changes when different sub-
group viruses are compared. When the positions of noncon-
servative amino acid changes between the two subgroup A
viruses are compared with the positions of nonconservative
amino acid changes between the two subgroup B viruses, 10
of the differences occur at exactly the same site or in
adjacent amino acids (Fig. 3). Thus, many of the differences
that distinguish two virus isolates from the same subgroup
occur at common sites in two other viruses from a different
subgroup. These differences identify seven regions that may
be type-specific sequence determinants. These regions are
labeled Ti through T7 in Fig. 3.
DISCUSSION
We examined at the molecular level two natural variants
of the ASLV retrovirus family. The variants are a virus that
has a tropism for mammalian cells (SR-D RSV) and a virus
that expresses type-specific antigenicity (RAV-1). Using
nucleotide sequence comparison, we searched for sequence
differences that may determine the variant phenotype of
each virus.
Molecular basis of mammal tropism. Although subgroup D
and B viruses can use the same receptor to infect chicken
cells, the pattern of infectivity of subgroup D viruses is
distinct from that of subgroup B viruses in two ways. (i)
Subgroup D viruses are able to infect mammalian cells (19).
(ii) They show a low level of infectivity on chicken cells that
are resistant to subgroup B viruses (19). It has been shown
previously that the env gene is a major determinant in
mammal tropism (6, 19, 25). We further refined the genetic
map for the mammal-tropic determinants by constructing a
molecular recombinant between subgroup A and D viruses.
The recombinant virus had a mammal-tropic host range,
which allows us to place the major mammal-tropic determi-
nants within the left half of the env gene, i.e., within the
gp85-coding domain.
There is obvious homology between the subgroup D virus
sequence and two subgroup B sequences within the gp85-
coding domain (Fig. 2). There are only 27 positions at which
the sequence of the subgroup D virus is distinct from that of
the subgroup B viruses within all of gp85, and in 16 of these
sites the sequence of the subgroup D virus is the same as that
of one of the other subgroup viruses. The subgroup D virus
has only 11 positions at which the amino acid is different
(Fig. 2, closed circles and triangles) when the subgroup D
sequence is compared with those of the other known sub-
groups. Thus, the determinants that confer mammal tropism
may represent small changes dispersed along the protein
chain, although the determinants could be juxtaposed in the
native protein.
Small sequence changes can alter the receptor specificity
of viral attachment proteins. In the case of influenza virus, a
single amino acid change results in altered specificity in the
recognition of sialic acid as a component of the receptor (42).
In addition, variants of influenza virus can recognize multi-
ple receptors, each with a different affinity (G. N. Rogers
and J. C. Paulson, Fed. Proc. 41:5880, 1982). Small changes
along the peptide chain of gp85 may, in a similar manner,
alter or expand the specificity of receptor interaction. By
analogy, the clustering of five subgroup D-specific amino
acids in hrl and hr2 (at sites where the subgroup B sequence
is also unique) may suggest two determinants involved
directly or indirectly in receptor interactions (Fig. 2, closed
circles).
The ability to infect mammalian cells is probably of little
biological significance, since such infections are nonproduc-
tive (52). However, an alternative pathway of infection may
provide certain viruses with a mechanism for infecting
chicken cells that are already infected, thus abrogating the
interference of superinfection that occurs when the secreted
viral glycoprotein masks the homologous receptor on the
surface of an infected cell (51). This interpretation is sup-
ported by the work of Bauer and Graf (2), in which they
showed that subgroup B viruses only partially interfere with
a superinfecting subgroup D virus, consistent with the pos-
sibility that subgroup D viruses have an alternative pathway
into cells in addition to the receptor used by subgroup B
viruses. Another explanation is that subgroup D viruses are
antigenic variants of subgroup B viruses that fortuitously
have an expanded host range. The five D- and B-unique sites
(Fig. 2, closed circles) are either in or adjacent to two
potential determinants of type-specific antigenicity, T3 and
T4 (see below).
Type-specific variation in antigenicity. ASLV of a given
subgroup are able to induce a neutralizing antibody response
in chickens that primarily recognizes viruses from that same
subgroup, thus defining one of the criteria for the subgroup
classification of these viruses (57). However, the antigenicity
of viruses within a given subgroup is not homogeneous, as
displayed by virus neutralization and cell surface immuno-
fluorescence with polyclonal antisera induced in chickens
(30; Table 2). Usually the neutralization titer is greatest
against the virus used to produce the antibody response; i.e.,
it is type specific. Subgroup- and typ,e-specific antigenicity
associated with virus neutralization has been identified both
with the gp85-gp37 complex (18, 56) and individually with
gp85 and gp37 (7). Our results with molecular recombinants
between two subgroup A viruses and between a subgroup A
virus and a subgroup E virus (Table 2) suggest that neutral-
izing antibodies in the polyclonal chicken antisera tested
react only with gp85.
To investigate the molecular basis of type-specific antige-
nicity, we compared the positions of differences in the
predicted amino acid sequence of the gp85-coding region of
two pairs of viruses representing two different subgroups
(Fig. 3). Comparison of two subgroup A viruses (RAV-1 and
SR-A RSV) revealed heterogeneity in six positions of poten-
tial glycosylation. In addition to these differences, there are
18 other scattered nonconservative amino acid changes.
Comparison of two subgroup B viruses (RAV-2 and MAV-B)
showed only 1 change in potential glycosylation sites and 15
other scattered nonconservative amino acid changes. Sur-
prisingly, 10 of the nonconservative amino acid changes
between the two subgroup A sequences occurred at or
adjacent to the positions of 10 of the nonconservative
changes between the two subgroup B sequences (Fig. 3).
The concurrence of the sites of change in the two compari-
sons identifies seven small domains (Ti through T7, Fig. 2)
that correlate with type specificity in these viruses. Two of
these domains are adjacent to positions of glycosylation site
heterogeneity.
A number of distinct antigenic differences associated with
virus neutralization must lie within the gp85 protein-coding
region of the two subgroup A viruses, as demonstrated by
the ANV-A1 recombinant virus (Table 2). It is likely that
these antigenic differences are associated with the differ-
VOL. 62, 1988
82 BOVA ET AL.
ences seen in the glycosylation pattern, the differences in the
primary amino acid sequence within gp85, or both types of
differences (Fig. 3). The subgroup B viruses RAV-2 and
avian myeloblastosis virus type 2 have also been shown to
express antigenic variability (30). However, we do not know
whether the subgroup B helper virus of avian myeloblastosis
virus that was sequenced by Kan et al. (32) and used in our
analysis corresponds to the avian myeloblastosis virus type
2, subgroup B, tested previously for antigenic variability by
Ishizaki and Vogt (30).
Structural similarities between the influenza virus hemag-
glutinin protein and the env gene product of avian retrovi-
ruses have been noted previously (29). The similarity be-
tween these two proteins is even more striking in light of the
potential role of sequence changes in altering the phenotype
of the protein. (i) Changes in the glycosylation pattern can
contribute to changes in the antigenicity of the hemagglutinin
protein (48). The variability in six potential glycosylation
sites between RAV-1 and SR-A RSV may also contribute to
the type-specific variation in antigenicity observed in these
viruses. (ii) Naturally occurring antigenic variants of influ-
enza virus arise from mutations in four specific domains in
the hemagglutinin protein (60). We identified seven domains
in which sequence variation coincided between two pairs of
viruses in different subgroups. Some or all of these domains
may be analogous to the four domains of the hemagglutinin
protein that lie on the outer surface of the protein molecule
and represent the primary sites of interaction with antibod-
ies. It is perhaps noteworthy that six of the seven type-
specific variable regions lie within the larger variable do-
mains, hrl and hr2, that correlate with subgroup specificity,
suggesting that the domains that confer subgroup-specific
antigenicity and receptor interaction also play a role in
defining type-specific antigenicity.
Antigenic variability may be important in determining the
disease course of retrovirus infection. This appears to be
especially true for the chronic disease state induced by
infection with lentiviruses. Both visna virus and equine
infectious anemia virus show sequence and antigenic varia-
tions during infection of a single host (10, 43). Among
different isolates of human immunodeficiency virus, se-
quence heterogeneity is greatest within the env gene (3, 50).
This variability in env is not random but appears to be
clustered in regions that may be determinants of antigenicity
(38). In all of these cases, the antigenic variability is proba-
bly a result of negative selection by the host immune system.
Thus, the changes seen in the env gene sequence of these
highly pathogenic viruses are likely to be results of a
common mechanism that is also responsible for the type
specificity of avian retroviruses.
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